Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumefantrine (DBL Institute for Health Research and Development)
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lumartem is a fixed-dose combination antimalarial drug containing artemether (20 mg) and lumefantrine (120 mg). It belongs to the artemisinin-based combination therapy (ACT) class, which is the standard of care for treating uncomplicated malaria caused by Plasmodium falciparum. Artemether, a semi-synthetic derivative of artemisinin, acts rapidly to reduce the parasite burden by interfering with hemoglobin metabolism and generating toxic free radicals that damage parasite proteins. Lumefantrine is a long-acting aryl amino alcohol that eliminates residual parasites to prevent recrudescence. Lumartem is specifically indicated for acute, uncomplicated malaria infections and is not used for severe or complicated cases or for prophylaxis. It is administered orally and dosed according to patient body weight.
- Brand names
- LumartemCoartem
- Other names
- artemether-lumefantrineAL
02
Targets
ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1)HemePfATP6 (Plasmodium falciparum ATP6)β-Hematin
Beyond the preview
Go deeper on artemether + lumefantrine (DBL Institute for Health Research and Development).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumefantrine (DBL Institute for Health Research and Development).